198 related articles for article (PubMed ID: 22266013)
1. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
2. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
Zhang X; Shi X; Li J; Hu Z; Guo F; Huang X; Zhang Z; Sun P; Jing Y; Gao J; Tan W
Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685
[TBL] [Abstract][Full Text] [Related]
3. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
4. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
[TBL] [Abstract][Full Text] [Related]
5. The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer.
Zhu YT; Zhao Z; Fu XY; Luo Y; Lei CY; Chen W; Li F; Pang SY; Chen SS; Tan WL
Stem Cell Res; 2014 Jul; 13(1):111-22. PubMed ID: 24874290
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.
Yin W; He Q; Hu Z; Chen Z; Qifeng M; Zhichun S; Zhihui Q; Xiaoxia N; Li J; Gao J
Vaccine; 2010 Jul; 28(31):4937-44. PubMed ID: 20653081
[TBL] [Abstract][Full Text] [Related]
8. Monitoring the response of orthotopic bladder tumors to granulocyte macrophage colony-stimulating factor therapy using the prostate-specific antigen gene as a reporter.
Wu Q; Esuvaranathan K; Mahendran R
Clin Cancer Res; 2004 Oct; 10(20):6977-84. PubMed ID: 15501977
[TBL] [Abstract][Full Text] [Related]
9. [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
Chen Z; Tan WL; Huang X; Liang ZK; Xu CX; Gao JM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):936-40. PubMed ID: 20501361
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer.
Zhang Z; Xu X; Zhang X; Chen X; Chen Q; Dong L; Hu Z; Li J; Gao J
Acta Oncol; 2011 Oct; 50(7):1111-8. PubMed ID: 21247263
[TBL] [Abstract][Full Text] [Related]
11. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
13. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
14. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
15. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
[TBL] [Abstract][Full Text] [Related]
16. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model.
Inoue H; Iga M; Xin M; Asahi S; Nakamura T; Kurita R; Nakayama M; Nakazaki Y; Takayama K; Nakanishi Y; Tani K
Cancer Immunol Immunother; 2008 Sep; 57(9):1399-411. PubMed ID: 18286286
[TBL] [Abstract][Full Text] [Related]
17. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
[TBL] [Abstract][Full Text] [Related]
18. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.
Inoue H; Iga M; Nabeta H; Yokoo T; Suehiro Y; Okano S; Inoue M; Kinoh H; Katagiri T; Takayama K; Yonemitsu Y; Hasegawa M; Nakamura Y; Nakanishi Y; Tani K
Cancer Sci; 2008 Nov; 99(11):2315-26. PubMed ID: 18957055
[TBL] [Abstract][Full Text] [Related]
19. [Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice].
Peng J; Shi X; Chen D; Liang Z; Lan K; Gao J; Tan W
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):807-11. PubMed ID: 22699059
[TBL] [Abstract][Full Text] [Related]
20. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
